With the exponential increase of interest in dry eye or ocular surface disease (OSD) among physicians and the industry, we are fortunate to have access to exciting new diagnostic and imaging technology as well as new treatment options and therapeutics for some of our most frustrated patients.
The Tear Film and Ocular Surface Society’s Meibomian Gland Workshop was tasked to sort through the literature to determine proper terminology of conditions affecting the lid margin. Review the terminology, gland anatomy, gland expression classifications, and treatment strategies.
Shire plc obtained U.S. Food and Drug Administration (FDA) approval for Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.
Seanna Grob MD, MAS, and Reza Dana, MD, MPH, MSc, present the second-place winning entry in Ophthalmology Times' Resident Writer's Award Program, sponsored by Allergan. In this case presentation, the treatment of dry eye disease in the setting of GVHD is a complicated condition that can have devastating effects if not diagnosed and treated in a timely fashion. Patients require close monitoring by an experienced cornea specialist and often need a combination of multiple available treatments to control symptoms and disease progression.